|
SoC Clinical Trials
5 actively recruiting trials across 3 locations
▲ +1 trial since August 2026
Pipeline
Phase 2: 2Phase 1/2: 3
Top Sponsors
- Universitaire Ziekenhuizen KU Leuven1
- UNC Lineberger Comprehensive Cancer Center1
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.1
- BioNTech SE1
- Arvinas Inc.1
Indications
- Cancer5
- Breast Cancer4
- Lung Cancer3
- Triple Negative Breast Cancer (TNBC), Early Setting1
- Liver Disease1
Los Angeles, California2 trials
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
UCLA Hematology Oncology - Main Site
Phase 1/2
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
USC Norris Comprehensive Cancer Center
Phase 1/2
Other1 trial
New Haven, Connecticut1 trial
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Yale Cancer Center Clinical Trials Office
Phase 2
Huntersville, North Carolina1 trial
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Clinical Trial Site
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.